Skip to main content

Table 1 Baseline characteristics of the included patients

From: Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial

 

Iron supplementation group (N = 15)

NYT group (N = 15)

P value

Age-years

45.1 ± 7.7

41.1 ± 8.3

0.52

Body mass index-kg/m2

21.4 ± 2.6

22.6 ± 2.7

0.27

Duration of intervention (IQR)-days

39.7 ± 23.0 (23, 50)

39.9 ± 20.3 (21, 58)

0.88

Disease-N (%)

  

1

 Benign

10 (67)

11 (73)

 

 Malignant

5 (33)

4 (27)

 

 Length of surgery-min

221 ± 158

190 ± 152

0.76

Menstruation-N (%)

  

1

 + 

14 (93)

15 (100)

 

 −

1 (7)

0 (0)

 

Hormonal therapy-N (%)

  

0.68

 + 

5 (33)

3 (20)

 

 −

10 (67)

12 (80)

 

Hemoglobin-g/dL

9.9 ± 0.8

9.8 ± 1.0

0.59

Hematocrit-%

32.3 ± 2.1

32.7 ± 2.1

0.77

Median serum iron level (IQR)-µg/dL

27 (14, 84) $

32 (15, 146) #

0.88

Median ferritin (IQR)-ng/mL

10 (5, 22) $

4 (3, 10) #

0.18

 CFS

  Physical

5.9 ± 5.1

7.1 ± 5.4

0.4

  Affective

6.5 ± 3.0

7.9 ± 4.1

0.38

  Cognitive

3.5 ± 3.7

2.8 ± 2.8

0.92

  Total

15.9 ± 9.3

17.9 ± 10.2

0.66

Median VAS-A (IQR)-mm

50 (8, 65)

56 (50, 70)

0.38

Median PSQI (IQR)

4 (3, 5)

5 (3, 7)

0.37

  1. Plus-minus values are mean ± standard deviation; analyzed with Wilcoxon rank sum test or Fisher’s exact test
  2. CFS cancer fatigue scale, VAS-A visual analogue scale for anxiety, PSQI Pittsburgh sleep quality index, IQR interquartile range
  3. $, N = 9; #, N = 8